Literature DB >> 27161435

MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.

Keiichiro Hattori1, Mamiko Sakata-Yanagimoto1, Yasushi Okoshi2,3, Yuki Goshima4, Shintaro Yanagimoto5, Rie Nakamoto-Matsubara1, Taiki Sato6, Masayuki Noguchi6, Shingo Takano7, Eichi Ishikawa7, Tetsuya Yamamoto7, Akira Matsumura7, Shigeru Chiba1.   

Abstract

Entities:  

Keywords:  MYD88 mutation; clinical sequencing; primary central nervous system lymphoma; targeted sequencing

Mesh：

Substances：

Year:  2016        PMID： 27161435     DOI： 10.1111/bjh.14080

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  18 in total

Review 1.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 2.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

3.  Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.

Authors:  Tarsheen K Sethi; Alexandra E Kovach; Natalie S Grover; Li-Ching Huang; Laura A Lee; Samuel M Rubinstein; Yang Wang; David S Morgan; John P Greer; Steven I Park; Mary Ann Thompson-Arildsen; Ashwini Yenamandra; Cindy L Vnencak-Jones; Nishitha M Reddy
Journal:  Leuk Lymphoma       Date:  2019-06-11

4.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

5.  Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.

Authors:  Wyndham H Wilson; George W Wright; Da Wei Huang; Brendan Hodkinson; Sriram Balasubramanian; Yue Fan; Jessica Vermeulen; Martin Shreeve; Louis M Staudt
Journal:  Cancer Cell       Date:  2021-11-04       Impact factor: 31.743

Review 6.  MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.

Authors:  Miguel Alcoceba; María García-Álvarez; Alejandro Medina; Rebeca Maldonado; Verónica González-Calle; María Carmen Chillón; María Eugenia Sarasquete; Marcos González; Ramón García-Sanz; Cristina Jiménez
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

7.  Expression of Tim-1 in primary CNS lymphoma.

Authors:  Wataru Kishimoto; Momoko Nishikori; Hiroshi Arima; Hiroaki Miyoshi; Yuya Sasaki; Toshio Kitawaki; Kotaro Shirakawa; Takeharu Kato; Yoshitaka Imaizumi; Takayuki Ishikawa; Hitoshi Ohno; Hironori Haga; Koichi Ohshima; Akifumi Takaori-Kondo
Journal:  Cancer Med       Date:  2016-10-05       Impact factor: 4.452

8.  High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment.

Authors:  Sisi Yu; Huaichao Luo; Meiling Pan; Luis Angel Palomino; Xiaoyu Song; Ping Wu; Jian-Ming Huang; Zhihui Zhang
Journal:  Oncol Lett       Date:  2017-11-22       Impact factor: 2.967

9.  Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.

Authors:  Maxime Fontanilles; Florent Marguet; Élodie Bohers; Pierre-Julien Viailly; Sydney Dubois; Philippe Bertrand; Vincent Camus; Sylvain Mareschal; Philippe Ruminy; Catherine Maingonnat; Stéphane Lepretre; Elena-Liana Veresezan; Stéphane Derrey; Hervé Tilly; Jean-Michel Picquenot; Annie Laquerrière; Fabrice Jardin
Journal:  Oncotarget       Date:  2017-07-18

Review 10.  Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.

Authors:  Alexander Baraniskin; Roland Schroers
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.